Navigation Links
Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
Date:5/20/2010

both locally and in distant sites in the body.  This cycle of JX-594 replication, cancer cell destruction, release and spread is then repeated.  Normal cells are not affected by JX-594 resulting in safety and tolerability.

The poxvirus strain backbone of JX-594 has been used safely in millions of people as part of a worldwide vaccination program.  This strain naturally targets cancer cells due to common genetic defects in cancer cells.  JX-594 was engineered to enhance this natural safety and cancer-selectivity by deleting its thymidine kinase (TK) gene, thus making it dependent on the cellular TK expressed at persistently high levels in cancer cells.  To enhance product efficacy, JX-594 is also engineered to express the GM-CSF protein.  GM-CSF complements the cancer cell lysis work of the product candidate, leading to a cascade of events resulting in tumor necrosis, tumor vasculature shutdown and an anti-tumoral immune attack.

About Jennerex

Jennerex is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer.  The Company's lead product JX-594, currently in an international randomized Phase 2 clinical trial for patients with primary liver cancer, demonstrated promising Phase 1 efficacy and safety results in patients with a diverse array of common cancers.  Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the Company's poxviruses in cancer cells.  These products not only cause cancer cell lysis thereby killing through replication, they simultaneously shut off the blood supply to tumors, as well as stimulating the body's immune response to the cancer.  Jennerex, Inc. is headquartered in

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
2. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
3. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
4. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
5. Jennerex Closes $5 Million First Tranche of Series C Financing
6. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
7. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Global polyvinyl chloride (PVC) demand registered a ... 2008-2009, especially in North America and Europe. However, the ... to a growing trend. , The largest chunk of ... construction segment. In 2013, the key PVC application spheres ... rigid film. Moreover, the PVC was consumed in the ...
(Date:10/30/2014)... October 30, 2014 SoundConnect ... provider, offers Office 365 end users the key ... complete phone system by adding voice enablement and ... includes Lync Online, a communication tool that includes ... With hosted voice, O365 becomes a comprehensive unified ...
(Date:10/30/2014)... 2014 Spartan Bioscience announced today that ... System . It detects CYP2C19 genetic mutations in less ... The Spartan RX CYP2C19 System is the first near-patient ... in Canada. Due to the system’s ease of use, ... by healthcare professionals such as doctors, nurses, pharmacists, and ...
(Date:10/30/2014)... Ras Al Khaimah, UAE (PRWEB) October 30, 2014 ... the appointment of Dr. James A. Manganello, Chairman of the ... (NSCEC) of The Bahamas. The appointment was made by ... The Bahamas on September 24th, 2014. , More ... Cell Therapy and Research Bill , Prime Minister Perry Christie ...
Breaking Biology Technology:Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 2Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 3SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 2SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 3Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 3
... (EMBL) discovered a new way to make use of drugs, ... how similar the side effects of different drugs are and ... molecule. The study, published in Science this week, ... often share target proteins, modes of action and unpleasant side ...
... ATRC ), a medical device company and a leader ... the second,quarter ended June 30, 2008 on Tuesday, August 5, ... a.m. ET on Tuesday,August 5, 2008 to discuss second quarter ... be available online from the investor relations,page of AtriCure,s corporate ...
... increased 38% to $42.3 million ... income rose 30% to $14.2 million, SHANGHAI, ... Board: CHBT) ("China-Biotics", "the,Company"), a leading Chinese firm ... of probiotics products,today announced its financial results for ...
Cached Biology Technology:Teaching old drugs new tricks 2AtriCure Announces Web Cast and Conference Call of Second Quarter 2008 Financial Results 2China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 2China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 3China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 4China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 5China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 6China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 7China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 8China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 9China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 10China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 11China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 12China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 13
(Date:10/31/2014)... a new test that can distinguish between birds that ... influenza virus or "bird flu" with those that have ... in the fight against this often fatal strain of ... of South East Asia, particularly Indonesia and Vietnam. , ... to humans and the threat of a pandemic if ...
(Date:10/31/2014)... , Oct. 30, 2014  HITLAB SM ... pleased to announce its inaugural HITLAB Innovators Summit ... University,s Low Library. HITLAB will partner with the ... Wellness, Blueprint Health, ProtoHack, Columbia Business School Alumni ... and Columbia Industrial Engineering and Operations Research, bringing ...
(Date:10/30/2014)... a $1.04 million grant from the U.S. Army ... osteoarthritis using a patient,s own stem cells, spurred ... polymers., Liping Tang, a bioengineering professor and interim ... is primarily focused on helping soldiers who are ... if we inject microscaffolding that we,ve developed into ...
Breaking Biology News(10 mins):New step towards eradication of H5N1 bird flu 2HITLAB Announces Inaugural HITLAB Innovators Summit 2HITLAB Announces Inaugural HITLAB Innovators Summit 3UTA researcher uses microscaffolding injections to mend cartilage, prevent osteoarthritis 2
... medication robbed Elma Phifer of her vision two decades ago ... reduced the ability of her eyes to soothe their damaged ... family and friends to help her do many of the ... twenty years and several life milestones later, Elma is able ...
... share a genetic profile that appears to be unique ... researchers at Cincinnati Children's Hospital Medical Center. The discovery ... specifically tailored to children who suffer from the severest ... Feb. 10 issue of the Journal of Allergy and ...
... throw a wrench in the transmissions of several speed demons ... Medicine in St. Louis and Harvard University have identified a ... slow cell invasion by malaria and other parasites known as ... March 15 issue of Proceedings of the National Academy of ...
Cached Biology News:Artifical cornea lets woman blind 20 years see 2Artifical cornea lets woman blind 20 years see 3Artifical cornea lets woman blind 20 years see 4Asthma gene clusters identified 2Asthma gene clusters identified 3Protein offers way to stop microscopic parasites in their tracks 2Protein offers way to stop microscopic parasites in their tracks 3
PMM2 Immunogen: PMM2 (NP_000294, 47 a.a. ~ 112 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
HOXC11 Antibody...
Rabbit polyclonal to Raf1 ( Abpromise for all tested applications). entrezGeneID: 5894 SwissProtID: P04049...
Sheep polyclonal to hCG beta core fragment ( Abpromise for all tested applications). Antigen: Full length native protein (purified) from human urine. Entrez GeneID: 1082 Swiss Protein ID...
Biology Products: